New Indications for Pembrolizumab Top SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. FDA Grants Priority Review to Rituximab for Children with 2 Rare Forms of Vasculitis
Genentech is seeking approval for rituximab (Rituxan) with glucocorticoids for pediatric patients with granulomatosis with polyangiitis and microscopic polyangiitis. Read more.
4. Mental Health Care in HIV Clinics Proves Beneficial
Expanded mental health care at HIV clinics across the United States could help in reaching the goal of viral suppression among 90% of the population. Read more.
3. FDA Approves Fifth Trastuzumab Biosimilar
The approval of Amgen’s trastuzumab-anns, the fifth biosimilar to Herceptin, marks the twentieth biosimilar approved by the FDA. Read more.
2. FDA Approves Polivy for Relapsed, Refractory Diffuse Large B-Cell Lymphoma
Polatuzumab vedotin-piiq (Polivy) is a first-of-its-kind anti-CD76b antibody-drug conjugate used in combination with bendamustine plus rituximab (Rituxan) for previously-treated diffuse large B-cell lymphoma. Read more.
1.FDA OKs Pembrolizumab for New Indications in Head and Neck Squamous Cell Carcinoma
Pembrolizumab is now indicated for use as a first-line monotherapy treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma. Read more.